Keryx Biopharma (KERX) Misses Q3 EPS by 19c

November 9, 2016 7:03 AM EST
Get Alerts KERX Hot Sheet
Trade KERX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.39), $0.19 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.37 million.

At September 30, 2016, the company had cash and cash equivalents of $132.2 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment